Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions
- 1 January 1993
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 31 (5) , 350-356
- https://doi.org/10.1007/bf00686147
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Quantitative matrix assisted plasma desorption mass spectrometryInternational Journal of Mass Spectrometry and Ion Processes, 1993
- Carboplatin and etoposide pharmacokinetics in patients with testicular teratomaCancer Chemotherapy and Pharmacology, 1989
- Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studiesEuropean Journal of Cancer and Clinical Oncology, 1987
- Drug monitoring of etoposide (VP16-213)Cancer Chemotherapy and Pharmacology, 1987
- Combined thin layer chromatography/mass spectrometry: An application of252Cf plasma desorption mass spectrometry for drug monitoringJournal of Mass Spectrometry, 1985
- Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumorsJournal of Neuro-Oncology, 1984
- Fractional sampling interface for combined liquid chromatography–mass spectrometry with 252CF fission fragment-induced ionizationJournal of Chromatography A, 1983
- High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- Multicompartment Pharmacokinetic Model of 4′-Demethylepipodophyllotoxin 9-(4,6-O-Ethylidene- β-D-glucopyranoside) in HumansJournal of Pharmaceutical Sciences, 1978
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975